Shiyao Group (01093): Phase II clinical trial of SYS6041 combined medication to treat recurrent ovarian cancer officially launched at the first center in China

Zhitongcaijing · 1d ago

Zhitong Finance App News, Shiyao Group (01093) announced that the Phase II clinical trial of SYS6041 (this product) developed by the Group in combination treatment of recurrent ovarian cancer has been officially launched at the first center in China.

This product is an antibody-conjugated drug targeting folic acid receptor α (FRα). It is registered and classified as a therapeutic biological product class 1. The antibody of this product binds specifically to the surface of cells expressing FRα and is internalized into the lysosome of the cell to release small molecule toxins — topoisomerase I inhibitors through specific shear by histoprotease in the lysosome, thereby killing tumor cells; at the same time, the product can nonspecifically remove surrounding tumor cells through bystander effects.

Previously, the Group had received the approval notice for the Phase II clinical trial of the combined drug issued by the State Drug Administration in June 2026. This clinical trial has now been carried out to evaluate the safety, tolerability and initial anti-tumor efficacy of the product in patients with recurrent ovarian cancer with different combination regimens. Currently, the recruitment and screening of test subjects is being actively promoted.